Tailoring lipid nanoparticles for application-specific mRNA delivery.

Authors

Xinxin Yan, Lixin Lin, Yifan Zhang, Xinyue Zhang, Lu Shi, Kexin Su, Menghao Yin, Mengyao Yu, Shun He, Tianrui Gu, Shuai Liu

Published in

Journal of controlled release : official journal of the Controlled Release Society. Pages 115386. Sep 21, 2026. Epub Sep 21, 2026.

Abstract

Expanding the therapeutic landscape of mRNA medicines to diverse applications necessitates delivery systems tailored to distinct biological requirements. However, beyond vaccine applications, current FDA-approved lipid nanoparticles (LNPs) are often directly used as their original vaccine formulations, substantially limiting their therapeutic potential. Rather than pursuing new ionizable lipids with uncertain safety profiles, we propose an application-oriented re-engineering strategy that leverages the clinically validated SM-102 platform, enabling rational LNP optimization for diverse mRNA delivery and therapeutic scenarios. Through systematic modulation of phospholipid component (e.g., 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC) and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE)) and lipid molar ratios, we tailor LNPs for transfection across representative cell types in vitro, systemic administration in vivo, and intramuscular delivery in vivo. Consequently, SM-102/DSPC and SM-102/DOPE LNPs emerge as preferred formulations for RAW 264.7 macrophages and IGROV1 ovarian cancer cells, respectively, achieving up to a 25.6-fold enhanced mRNA delivery over original SM-102 LNPs in vitro. For intravenous administration, optimal SM-102/DSPC LNPs enable 2.3-fold enhanced hepatic mRNA delivery compared to original SM-102 LNPs. In contrast, intramuscular injection preferentially benefits from SM-102/DOPE LNPs, achieving 17.7-fold higher muscular expression and 22.0-fold enhanced lymph node delivery than SM-102 LNPs. All optimized formulations show comparable tolerability to the clinically validated SM-102 LNPs. This study supports an application-specific tailoring platform that enables the rational selection of appropriate mRNA delivery systems for diverse therapeutic scenarios.

PMID:
42767379
Bibliographic data and abstract were imported from PubMed on 22 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.